Turkish Journal of Internal Medicine

Yazarlar: ["Burcu YAĞIZ", "Belkıs Nihan COŞKUN", "Zeliha Kübra ÇAKAN", "Gamze UÇAN GÜNDÜZ", "Özgür YALÇINBAYIR", "Serkan YAZİCİ", "Hayriye SARICAOĞLU", "Hüseyin Ediz DALKILIÇ", "Yavuz PEHLİVAN"]

Konular:-

DOI:10.46310/tjim.1144532

Anahtar Kelimeler:Behcet,Dermatology,Ophthalmology,Rheumatology,TNF-α inhibitor

Özet: Background Comparing treatment modalities is difficult in Behcet's syndrome, even if tumour necrosis factor-alpha (TNF-α) inhibitors are a treatment option for all involvements resistant to conventional therapy. This study evaluated how different departments dealt with treatment, particularly with TNF-α inhibitors. Material and Methods The study comprised 111 patients from our Behcet's syndrome cohort who were treated with TNF-α inhibitors between 2010 and 2019. Data on patients were retrieved retrospectively from the rheumatology, ophthalmology, and dermatology clinics' patient records. Results Patients followed up in rheumatology (n: 40) were classified as Group 1, and patients followed up in ophthalmology (n: 49) and dermatology (n: 5) as Group 2. In Group 1, genital ulcers, erythema nodosum (p=0.009, p=0.003, respectively), lower extremity deep vein thrombosis, arterial aneurysm and neurological involvement were more common (p=0.005, p=0.008, p=0.001, respectively). In Group 2, the use of cyclosporine and interferon-α before the anti-TNF agent was higher (p<0.001, p<0.001, respectively), and the use of cyclophosphamide were higher in Group 1 (p<0.001). Both groups preferred infliximab, and ocular involvement was the most common reason for starting. Conclusions While TNF-α inhibitors were chosen equally across departments, conventional medicines, including cyclosporine, cyclophosphamide, and interferon-α, were not. This choice was determined by the departments' experience and the clinical traits that predominated.

---